Adarx 制药
ADRX
17.65
-0.05
-0.28%
Adarx 制药
US · ADRX
#2823 按市值排名
上市于 2026
17.65
-0.05
-0.28%
实时 - 追踪5344个代码 - 心跳于393秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量增加了5家。
- 机构持股总比例上升了49.4个百分点。
机构持股
- 机构持股比例
- 49.36% +49.36pp
- 机构数量
- 5 +5
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近7个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
VC/PE Fund44.78%
Individual/Insider12.70%
Private Company4.58%
Other37.94%
主要股东 截至 2026-10-02
OrbiMed Advisors LLC
22.13% · 24.79M 股
Eli Lilly Investment Consulting (Shanghai) Co., Ltd.
10.58% · 11.86M 股
SR One Capital Management, LP
8.87% · 9.94M 股
Zhen Li
5.23% · 5.86M 股
Li Zhen
5.23% · 5.86M 股
Bcls Fund III Investments, Lp
4.58% · 5.13M 股
TCG Crossover Management, LLC
3.20% · 3.59M 股
Rui Zhu
2.24% · 2.51M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪19份申报 · 10次买入 · 0次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| OrbiMed Advisors LLC | -- | 22.13% |
| Eli Lilly Investment Consulting (Shanghai) Co., Ltd. | -- | 10.58% |
| Li Zhen | -- | 5.23% |
| Rui Zhu | Chief Technology Officer | 2.24% |
| Mary Tagliaferri | Independent Director | -- |
| Ying Huang | Independent Director | -- |
| SR One Capital Management, LP | -- | -- |
| Robert Ackles | Chief Human Resources Officer | -- |
| A. MacLeod | Chief Scientific Officer | -- |
| Ryan Fisk | CFO & Chief Business Officer | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-27 | OrbiMed Advisors LLC | -- | Private Acquisition | +950,000 | $17.00 |
| 2026-09-27 | OrbiMed Advisors LLC | -- | Derivative Exercise and Retained | +23,255,789 | -- |
| 2026-09-27 | Eli Lilly Investment Consulting (Shanghai) Co., Ltd. | -- | Derivative Exercise and Retained | +11,858,655 | -- |
| 2026-09-27 | SR One Capital Management, LP | -- | Private Acquisition | +1,600,000 | $17.00 |
| 2026-09-27 | SR One Capital Management, LP | -- | Derivative Exercise and Retained | +8,336,661 | -- |
| 2026-09-23 | Mary Tagliaferri | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-09-23 | Ying Huang | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-09-23 | Li Zhen | -- | Other Derivative Acquisition | +1,024,152 | $17.00 |
| 2026-09-23 | Li Zhen | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-09-23 | Robert Ackles | Chief Human Resources Officer | Other Derivative Acquisition | +85,346 | $17.00 |
| 2026-09-23 | Robert Ackles | Chief Human Resources Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-09-23 | A. MacLeod | Chief Scientific Officer | Other Derivative Acquisition | +170,692 | $17.00 |
| 2026-09-23 | A. MacLeod | Chief Scientific Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-09-23 | Ryan Fisk | CFO & Chief Business Officer | Other Derivative Acquisition | +170,692 | $17.00 |
| 2026-09-23 | Ryan Fisk | CFO & Chief Business Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-09-23 | Rui Zhu | Chief Technology Officer | Other Derivative Acquisition | +512,076 | $17.00 |
| 2026-09-23 | Rui Zhu | Chief Technology Officer | Initial Statement of Beneficial | 0 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
Adarx 制药 讨论区 0 条评论